Press Release: 2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
26 September 2024 Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community. The award was virtually presented to Professor Bandmann as…
Press Release: Cure Parkinson’s welcomes Mike Ashton as new chair of trustees
18 June 2024 Mike Ashton joined the board towards the end of 2023, bringing with him extensive experience in business growth strategy, brand and marketing management and governance in both the private and charity sectors. Mike said: “I’ve been impressed and inspired by everything I’ve…
Press Release: Fundraiser of the Year 2023
11 April 2024 We are thrilled to announce that we have two winners of our 2023 Fundraiser of the Year Award: Antony Rose and Michelle Gillies! These two incredible supporters went ‘above and beyond’ to support our vital research by spending 2023 raising funds and…
Press Release: Phase 2 clinical trial of Type 2 diabetes drug for treatment of Parkinson’s shows positive and promising results
3 April 2024 Results from a one-year, phase 2 clinical trial of the Type 2 diabetes drug lixisenatide suggest that the treatment may slow the progression of motor symptoms in Parkinson’s disease. The study is published on 4 April in The New England Journal of…
Press Release: Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
23 February 2024 Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s. The DAPA-PD trial will evaluate the safety and tolerability…